# Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).

> **NCT06654700** · PHASE3 · NOT_YET_RECRUITING · sponsor: **MAXVAX Biotechnology Limited Liability Company** · enrollment: 1200 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Recombinant Zoster Vaccine (CHO Cell)

## Key facts

- **NCT ID:** NCT06654700
- **Lead sponsor:** MAXVAX Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-09
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06654700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06654700, "Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06654700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*